Trial
NCT04863248
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
G1 Therapeutics, Inc.
Collaborators
—
Condition
Metastatic Non-Small Cell Lung Cancer
Intervention
Trilaciclib
Why stopped
Treatment paradigm in second- and third-line NSCLC is shifting away from docetaxel, the backbone chemotherapy therapy used in this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-04-14